ProCE Banner Activity

CE / CME

Current and Emerging Therapeutic Strategies Targeting BCMA for Relapsed/Refractory Multiple Myeloma: Guidance for the Community Multidisciplinary Team

Video

Watch this on-demand webcast from an interdisciplinary team workshop on current and emerging BCMA-targeted therapies for the treatment of patients with multiple myeloma.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 15, 2023

Expiration: August 14, 2024

Share

Faculty

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Carol Ann Huff

Carol Ann Huff, MD

Associate Professor of Medicine and Oncology
Multiple Myeloma Program
Medical Director
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University 
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb

Regeneron Pharmaceuticals, Inc

Target Audience

This program is intended for hematologists, oncologists, nurses, pharmacists, and other HCPs on the multidisciplinary team caring for patients with multiple myeloma.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge of, competence in, and performance in applying practice-changing clinical data and expert recommendations to integrate the use of BCMA-targeted agents for their patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe to patients the advantages and disadvantages for the 3 mechanisms of action for targeting BCMA

  • Identify patients with multiple myeloma who are likely to benefit from treatment with currently available BCMA-targeted therapy

  • Plan therapeutic strategies using BCMA-targeted therapies for patients with multiple myeloma, considering available efficacy, safety, and tolerability data along with guideline and expert recommendations

  • Identify mechanisms of resistance that can affect sequential use of BCMA-targeting agents

  • Monitor and mitigate potential adverse events from anti-BCMA therapy in patients with multiple myeloma, including but not limited to ocular toxicity, cytokine-release syndrome, and neurotoxicity

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Carol Ann Huff, MD

Associate Professor of Medicine and Oncology
Multiple Myeloma Program
Medical Director
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University 
Baltimore, Maryland

Carol Ann Huff, MD: consultant/advisor/speaker: Janssen, Sanofi; researcher: Prothena.

Program Director

Suzanne Lentzsch, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch, MD, PhD: consultant/advisor/speaker: Adaptive, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, PerView, RedMed, Regeneron, Sanofi, Takeda; researcher: Sanofi, Zentalis; stock/stock options: Magenta, Poseida; royalties or patent beneficiary: Caelum Bioscience.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; independent contractor: TG Therapeutics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 15, 2023, through August 14, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

A logo for a companyDescription automatically generated with low confidence

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008176-0000-23-205-H01-P.
Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days